Oral K9
Diabetic Macular Edema (DME)
Key Facts
About Inflammasome Therapeutics
Inflammasome Therapeutics is a private, clinical-stage biotech pioneering a new approach to treating degenerative diseases by targeting chronic inflammasome activation. Its platform is built upon the discovery that certain FDA-approved nucleoside reverse transcriptase inhibitors (NRTIs) inhibit inflammasomes, supported by epidemiological data showing reduced disease incidence in patients taking these drugs. The company has developed safer derivatives called Kamuvudines (K8, K9) and is advancing them in clinical trials for ocular indications including Geographic Atrophy, Diabetic Macular Edema, and Thyroid Eye Disease.
View full company profileAbout Inflammasome Therapeutics
Inflammasome Therapeutics is a private, clinical-stage biotech pioneering a new approach to treating degenerative diseases by targeting chronic inflammasome activation. Its platform is built upon the discovery that certain FDA-approved nucleoside reverse transcriptase inhibitors (NRTIs) inhibit inflammasomes, supported by epidemiological data showing reduced disease incidence in patients taking these drugs. The company has developed safer derivatives called Kamuvudines (K8, K9) and is advancing them in clinical trials for ocular indications including Geographic Atrophy, Diabetic Macular Edema, and Thyroid Eye Disease.
View full company profile